Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications

The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Meizoso, Jonathan P., Moore, Hunter B., Moore, Ernest E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American College of Surgeons. Published by Elsevier Inc. 2021
Materias:
Collective Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982779/
https://www.ncbi.nlm.nih.gov/pubmed/33766727
http://dx.doi.org/10.1016/j.jamcollsurg.2021.02.019
Descripción
Sumario:The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by a high incidence of fibrinolysis shutdown. The aims of this review were to describe the manifestations of fibrinolysis shutdown in COVID-19 and its associated outcomes, review the molecular mechanisms of dysregulated fibrinolysis associated with COVID-19, and discuss potential implications and therapeutic targets for patients with severe COVID-19.

Ejemplares similares